138 results about "Benign tumor" patented technology

A tissue protective system and method having particular application in thermoablative surgical therapies where heat or cold is used to create a kill zone for treating cancer cells as well as malignant or benign tumors in a targeted internal tissue area (e.g., the prostate) of a patient while sparing an adjacent benign internal tissue area (e.g., a neurovascular bundle). One of a hollow sheath or a balloon that is carried by a balloon catheter is located within an access opening that is made by a needle trocar inserted between the targeted tissue area in need of treatment and the benign tissue area to be protected in order to hold the protected tissue area off the targeted tissue area and away from the lethal temperature of the kill zone. The balloon of the balloon catheter is inflated in the access opening via a balloon channel which runs longitudinally through the catheter. At least one temperature sensor is mounted on the balloon and responsive to the temperature near the benign tissue area to be protected. Heat or cold is provided to the balloon from a heating wire or a circulating fluid, depending upon the temperature that is sensed by the temperature sensor.

An ingestible pill platform for colon imaging is provided, designed to recognize its entry to the colon and expand in the colon, for improved imaging of the colon walls. On approaching the external anal sphincter muscle, the ingestible pill may contract or deform, for elimination. Colon recognition may be based on a structural image, based on the differences in diameters between the small intestine and the colon, and particularly, based on the semilunar fold structure, which is unique to the colon. Additionally or alternatively, colon recognition may be based on a functional image, based on the generally inflammatory state of the vermiform appendix. Additionally or alternatively, pH, flora, enzymes and (or) chemical analyses may be used to recognize the colon. The imaging of the colon walls may be functional, by nuclear-radiation imaging of radionuclide-labeled antibodies, or by optical-fluorescence-spectroscopy imaging of fluorescence-labeled antibodies. Additionally or alternatively, it may be structural, for example, by visual, ultrasound or MRI means. Due to the proximity to the colon walls, the imaging in accordance with the present invention is advantageous to colonoscopy or virtual colonoscopy, as it is designed to distinguish malignant from benign tumors and detect tumors even at their incipient stage, and overcome blood-pool background radioactivity.

Oral formulations of pharmaceuticals are provided with enhanced bioavailability by targeting specific regions of the gastrointestinal tract. Particularly, water soluble and acid-labile drugs such as cytidine analogs (e.g., decitabine) and 2'-deoxyadenosine analogs (e.g., pentostatin) are formulated with pH-sensitive polymers so that these drugs are preferably absorbed in the upper regions of the small intestine, such as the jejunum. In addition, drugs with poor oral bioavailability such as camptothecin compounds (e.g., 9-nitro-camptothecin) can also be formulated using similar strategies in order to significantly improve their oral bioavailability. These formulations can be used to treat a wide variety of diseases or conditions, such hematological disorders, benign tumors, cancer, restenosis, inflammatory diseases, and autoimmune diseases.

Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin(TM), interferons, andanti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells. Matrices can be formed of synthetic or natural materials, by chemical coupling at the time of implantation, using standard techniques for formation of fibrous matrices from polymeric fibers, and using micromachining or microfabrication techniques. These devices and strategies are used as delivery systems via standard or minimally invasive implantation techniques for any number of parenterally deliverable recombinant proteins, particularly those that are difficult to produce in large amounts and / or active forms using conventional methods of purification, for the treatment of a variety of conditions that produce abnormal growth, including treatment of malignant and benign neoplasias, vascular malformations (hemangiomas), inflammatory conditions, keloid formation, abdominal or plural adhesions, endometriosis, congenital or endocrine abnormalities, and other conditions that can produce abnormal growth such as infection. Efficacy of treatment with the therapeutic biologicals is detected by determining specific criteria, for example, cessation of cell proliferation, regression of abnormal tissue, or cell death, or expression of genes or proteins reflecting the above.

Method and apparatus performing dynamic contrast-enhanced-magnetic resonance imaging on tissue to obtain a plurality of datasets of images. Principal component analysis is performed on each dataset to obtain a covariance matrix and its corresponding eigenvalues and eigenvectors and produce a common base of eigenvectors. The dominant eigenvectors that are not associated with instrumental and random noise, commonly the 2nd eigen-state and the 3rd eigenvectors, or the 1st and 2nd eigen vectors, are correlated with the physiological relevant parameters of the 3TP method to obtain a hybrid method. The fusion of the eigenvectors with the 3TP parameters is dictating a rotation of the two relevant eigenvectors to obtain new rotated eigenvectors that serve to calculate new projection coefficient maps of the rotated eigenvectors for the imaged tissue indicative of physiological relevant parameters reflecting wash-out and wash-in patterns that detect abnormal tissue and distinguishes between cancerous and benign tumors. Computer-readable medium containing program instructions for carrying out the above.

The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of said glycans and reagents binding to them for the diagnostics of cancer and malignancies. Furthermore, the invention is directed to the use of said glycans and reagents binding to them for the treatment of cancer and malignancies. Moreover, the present invention comprises efficient methods to differentiate between malignant and benign tumors by analyzing glycan structures.

A method for treating diseases associated with abnormal cell proliferation comprises delivering to a patient in need of treatment a compound selected from the group consisting of 20(S)-camptothecin, analog of 20(S)-camptothecin, derivative of 20(S)-camptothecin, prodrug of 20(S)-camptothecin, and pharmaceutically active metabolite of 20(S)-camptothecin, in combination with an effective amount of one or more agents selected from the group consisting of alkylating agent, antibiotic agent, an alkylating agent, antibiotic agent, antimetabolic agent, hormonal agent, plant-derived agent, anti-angiogenesis agent and biologic agent. The method can be used to treat benign tumors, malignant or metastatic tumors, leukemia and diseases associated with abnormal angiogenesis.

The present invention provides therapy and methods for the treatment and prevention of diseases of cell proliferation such as cancer, benign tumors, and viral diseases such as HIV-AIDS, hepatitis B, hepatitis C and cirrhosis. The methods of this invention consist of the administration to a patient of a combination of effective amounts of agents capable of eradicating the neoplastic cells, while sparing the non-neoplastic cells from cytotoxic side-effects. The agents co-administered in therapeutically effective amounts are: chemotherapeutic agents, apoptotic agents, anti-angiogenic agents, cell differentiation agents, immunomodulating agents, antioxidants, vitamins, microelements, enzymes and natural extracts.

The invention provides a traditional Chinese medicine composition for treating hyperplasia of mammary glands. The traditional Chinese medicine composition is prepared from the ingredients in parts by weight: bupleurum root, nutgrass galingale rhizome, green tangerine peel, angelica sinensis, chuanxiong rhizome, salvia miltiorrhiza, manis pentadactyla Linnaeus, rhizoma zedoariae, raw oyster shell, radix astragali, poria cocos, seaweed, herba leonuri, rhizoma sparganii, deer horn, dried old orange peel, peach kernel, thunberg fritillary bulb, selfheal spike, frankincense, codonopsis pilosula, tangerine seed, glycyrrhiza uralensis, rhubarb root, cowherb seed, safflowers, radix curcumae, luffa cylindrica, radix asparagi, dandelions, rhizoma pleionis, curculigo orchioides, evodia, epimedium, myrrha, litchi seed and radix isatidis. The traditional Chinese medicine composition provided by the invention is used for treating diseases such as hyperplasia of mammary glands, benign tumor of mammary glands and hysteromyoma, is remarkable in effect and is free of toxic or side effects, the effective rate of treatment reaches 95%, and recurrence is difficult.

The invention discloses a three-way-decision-based liver tumor CT image classification method. A classifier is trained; image preprocessing and feature extraction are carried out on a marked liver CT image training sample to form a feature vector; rule extraction is carried out by using an attribute reduction method to form a knowledge base, thereby providing a basis for follow-up case classification diagnoses. T-be-classified cases are processed image pretreatment to extract liver regions, hepatic vessels, and liver tumors; 14 case features are calculated; the case feature values are inputted into a three-way-decision-based classifier; and then cases are classified into three types: a benign tumor, a malignant tumor, and an uncertain tumor. Therefore, a doctor can make different therapeutic regimens for different tumor types.

Methods for detecting and measuring metabolic changes useful in the detection of cancer, and in differentiating between ovarian cancer and benign ovarian tumor are described, as well as the unexpected and valuable combination of detecting both lipidomic and aqueous metabolites. Two independent LC-MS-based metabolomics platforms, including a global lipidomics approach, were used to screen for differentially abundant plasma metabolites between cases with serous ovarian carcinoma and controls with benign serous ovarian tumor. The identified biomarkers can be used to distinguish between ovarian cancer and benign tumors. Standards and kits for use with the methods for detecting cancer are also provided.

The present invention relates to an optically pure alpha- ketoacyl harringtonine and a preparing and purifying method thereof. In the temperature of -80 DEG C to 50 DEG C, the alpha-ketoacyl chlorine which is prepared through reacting alpha-ketonic acid and oxalyl chloride reacts with the cephalotaxine in an inert organic solvent while the organic base is used as an acid-binding agent for obtaining the oily product represented by the formula (I). The purifying steps are as follows: dissolving the oily product with the inert organic solvent, adding the saturated NaHSO3 solution, mixing and separating the liquid; after washing the water phase with the organic solvent, adjusting the pH of the water phase with saturated NaHSO3 solution to 7-8, extracting with the organic solvent; washing the organic phase with the buffering solution with pH of 6.8 and the saturated saline solution, drying and filtering the organic phase, removing the solvent for obtaining the pale-yellow solid; and then recrystallizing with the organic dissolvent for obtaining the white solid or colorless crystal. The optically pure alpha- ketoacyl harringtonine is a key intermediate for synthesizing the medicine of harringtonine alkaloid, which is widely applied for anti-tumor (malignant tumor and benign tumor), antiparasitic, antifungal and antibacterial chemotherapy. The synthesizing method is suitable for purifying and preparing the large amount of optically pure compound represented by the structural formula of (I).

An application of three-dimensional photoacoustic imaging in a breast tumor scoring system includes the following steps: (1) image information of breast tumor is collected by photoacoustic / ultrasonicdual-mode imaging in vitro; (2) the collected image information is analyzed and morphological scoring and functional scoring are performed respectively; and (3) by combining the results of morphological scoring and functional scoring, a comprehensive score is obtained and whether the breast tumor has a malignant tendency result or not is judged; and if one or all of the morphological scoring or functional scoring are judged as malignant tendency, the tumor is considered as malignant tendency. More stable quantitative results can be provided through three-dimensional tumor imaging. In addition,compared with single breast three-dimensional photoacoustic imaging, a tumor area is depicted by ultrasound imaging, the external and internal characteristics of the tumor can be analyzed respectively, and the diagnostic sensitivity and specificity are improved. In addition, malignant and benign tumors are distinguished based on the critical value of oxygen saturation (SO2), and the method is more convenient, highly repeatable and objective in diagnosis.

A panel of biomarkers for the diagnosis and treatment of breast cancer was examined in the saliva of a cohort of 1) healthy women, 2) women with benign lesions of the breast and 3) women with diagnosed breast cancer. Recognized tumor markers c-erbB-2 (erb), cancer antigen 15-3 (CA 15-3), and tumor suppresser oncogene protein 53 (p53) were found in the saliva of all three groups of women. The levels of erb and CA 15-3 in the cancer patients evaluated, however, were significantly higher than the salivary levels of healthy controls and benign tumor patients. Conversely, pantropic p53 levels were higher in controls as compared to those women with breast cancer and those with benign tumors.

The invention discloses a medicine for treating tumors and a preparation method thereof. The medicine is prepared from a turtle shell, curcuma zedoary, dried toad skin, rabdosia rubescens, lily, coix seeds, rhizoma polygonati, ligusticum wallichii, subprostrate sophora, salviae miltiorrhizae, ground beeltle, radix curcumae, uniflower swisscentaury root, clematis chinensis, solanum lyratum, nightshade, oldenlandia diffusa, sculellaria barbata, notoginseng powder and auxiliary materials. The medicine disclosed by the invention has the effects of resolving hard lumps, and detoxicating and activating blood (nourishing yin, promoting blood circulation, removing stasis, and disintegrating masses), and is suitable for subcutaneous nodule, phlegm-damp oozing in the body, abdominal mass in the body, and various cancers, malignant and benign tumors in western medicine diagnosis; and the prepared medicine is significant in curative effect, and small in toxic and side effects.

Method and apparatus performing dynamic contrast-enhanced-magnetic resonance imaging on tissue to obtain a plurality of datasets of images. Principal component analysis is performed on each dataset to obtain a covariance matrix and its corresponding eigenvalues and eigenvectors and produce a common base of eigenvectors. The dominant eigenvectors that are not associated with instrumental and random noise, commonly the 2nd eigen-state and the 3rd eigenvectors, or the 1st and 2nd eigen vectors, are correlated with the physiological relevant parameters of the 3TP method to obtain a hybrid method. The fusion of the eigenvectors with the 3TP parameters is dictating a rotation of the two relevant eigenvectors to obtain new rotated eigenvectors that serve to calculate new projection coefficient maps of the rotated eigenvectors for the imaged tissue indicative of physiological relevant parameters reflecting wash-out and wash-in patterns that detect abnormal tissue and distinguishes between cancerous and benign tumors. Computer-readable medium containing program instructions for carrying out the above.

The invention provides a breast cancer histopathological type classification method based on generative adversarial network screening image blocks, which comprises the following steps: acquiring a breast cancer histopathological type image data set, and further comprises the following steps: preprocessing breast cancer histopathological type images; enabling the generative adversarial network to screen normal regions in the benign image blocks and the malignant image blocks; enabling the generative adversarial network to screen benign regions in the malignant image blocks; and classifying thebreast cancer histopathological images by using a convolutional neural network based on cyclic dense connection. According to the invention, the improved unsupervised generative adversarial network isadopted to learn the data distribution of the normal pathology image and the benign tumor pathology image respectively, so that the benign tumor area and the normal area in the malignant tumor pathology image and the normal area in the benign tumor pathology image can be screened; and the possibility is provided for assisting doctors to diagnose the illness state more accurately and more quicklyto the maximum extent.

The invention discloses a breast tumor ultrasonic image classification method based on a three-dimensional convolutional neural network, and relates to the technical field of computer image processing. The method comprises the specific steps that data preprocessing is carried out, a training set is used for training a proposed three-dimensional convolutional neural network, benign tumors are marked as 0, and malignant tumors are marked as 1; testing the trained model by using a test set, and finally outputting the probability of benign and malignant tumors through a softmax function, extracting regions of interest, and performing tumor probability estimation on each region of interest by using a three-dimensional convolutional neural network; diversity, namely complexity, of breast cancerimages causes certain difficulties to diagnosis of doctors, the misdiagnosis rate of tumors can be effectively reduced through automatic classification of breast tumor ultrasonic images based on deeplearning, and meanwhile reliable reference bases can be provided for diagnosis of the doctors.

The invention provides a construction method and device of benign and malignant tumor identification model, and the method comprises the steps: taking a plurality of known benign tumor samples and malignant tumor samples as a training set, and obtaining TCR clone types and CDR3 segments of the samples in the training set; counting and calculating the occurrence frequency of the CDR3 section, and then recoding the CDR3 section through Kmer interruption; carrying out data dimension reduction processing on the Kmer frequency data obtained after CDR3 recoding; associating benign and malignant information of a known tumor sample in the training set with the Kmer data after data dimension reduction, and performing model training by using a machine learning algorithm to obtain a benign and malignant tumor identification model. The benign and malignant tumor identification model constructed by the construction method is used for carrying out benign and malignant tumor identification on unknowntumor samples, can identify benign and malignant tumor samples of different types, and meets the requirements of broad spectrum and specificity.

A method for determining if a subject with cancer or precancerous lesions or a benign tumor, will respond to treatment with an inhibitor selected from the group comprising an inhibitor of one or more enzymes in the mevalonate pathway, an inhibitor of geranylgeranyl transferase, an inhibitor of farnesyl transferase or an inhibitor of squalene synthase, by (i) obtaining a sample of the cancer cells, precancerous cells or benign tumor cells from the subject, (ii) assaying the cells in the sample for the presence of a mutated p53 gene or a mutant form of p53 protein or a biologically active fragment thereof, and (iii) if the cells have the mutated p53 gene or mutant form of the p53 protein, then determining that the subject will respond to treatment with the inhibitor or combinations thereof. Some embodiments are directed to treatment with the inhibitors.

The present invention provides uses of TRPV4 antagonists in the treatment or prevention of hydrocephalus symptoms, also known as hydrocephaly, including hydrocephalus as a result of any structural defect, any metabolic defect, any injury (direct force to the head, indirect force to the head, shock waves, pressure changes, etc.), any insult (microbial, chemical, toxins, allergic reactions or other inflammatory process, or other pathology, eg. cancer, benign tumor, etc.). Related materials and methods are also provided herein.

A Chinese and western composite medicine for treating neoplastic diseases is characterized by comprising Chinese herbal medicinal ingredients and a western medicinal ingredient which are mixed, the Chinese herbal medicinal ingredients include 5 polyzyme tablets and a stomach invigorating and digestion aiding tablet, each polyzyme tablet comprises pepsin, trypsin, pancreatic lipase and amylopsin, and the stomach invigorating and digestion aiding tablet comprises radix pseudostellariae, tangerine peels, Chinese yam, (roasted) malt and hawthorn; the western medicinal ingredient is ceftriaxone sodium injection solution; and the weight of each polyzyme tablet is 0.313g, the total weight of the polyzyme tablets is 1.57g, the weight of the stomach invigorating and digestion aiding tablet is 0.8g, the weight of the ceftriaxone sodium injection solution is 0.75g, and the Chinese herbal medicinal ingredients and the western medicinal ingredient are combined to form the prescription. The Chinese and western composite medicine for treating the neoplastic diseases is particularly used for suppressing and killing pathogenic bacteria capable of causing benign tumor and malignant tumor infection of tissue cells of a human body, the composite medicine is directly dripped into the oral cavity or an affected part of the human body when the human body suffers from the tumor infection, and 3-4 drops of the composite medicine are applied every time. The Chinese and western composite medicine has few side effects, becomes effective within 30 minutes and does not injure the liver, the brain and the kidneys of the human body.

The invention discloses a molecular marker for diagnosis and treatment of pituitary adenoma. Pituitary adenoma is a common intracranial benign tumor and can induce endocrine symptoms as well as intracranial hypertension and change of vision and view. Experiments prove that the expression of PAEP gene in the pituitary adenoma tissue is up-regulated, and the expression of the PAEP gene can inhibit the proliferation of pituitary adenoma cells and promote the apoptosis of the pituitary adenoma cells. The invention provides a new molecular means for the diagnosis and treatment of pituitary adenoma.

The invention discloses a method used for differentiating benign tumor (pulmonary sclerosing pneumocytoma) and malignant tumor (adenocarcinoma in situ) based on infrared light spectrums. The method comprises following steps: benign tumor and malignant tumor tissue slices are collected, slice infrared transmitted spectrums are collected at 4000 to 1900cm<-1> range at a resolution ratio of 8cm<-1> and scanning time of 64; the obtained spectrums are not subjected to pretreatment, or are subjected to SGS pretreatment, mole construction spectrum range upper limit is determined to be 4000 to 3960cm<-1>, the lower limit is determined to be 1960cm<-1>, the former 4 to 9 main ingredients are selected, discriminant analysis method or counter propagation network are adopted to construct a model usedfor differentiating benign tumor and malignant tumor; a property unknown tumor tissue slice is selected, and spectrum data processing is carried out through the above steps, and at last the constructed model is adopted for prediction. The method can be used for accurate, objective, rapid, and economical differentiating of benign tumor and malignant tumor.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

The invention relates to the technical field of medical diagnostics. Thyroid tumors can be divided into two types including benign tumors and cancers. The property of a thyroid nodule is difficult to determine clinically; and even if biopsy is carried out, the benign tumors and the cancers are not easy to clearly identify due to thyroid adenomas and focal nodular hyperplasia. The invention provides a blood micro-molecular metabolin specific chromatogram which is used for identifying papillary thyroid carcinomas, benign thyroid tumors and blood of normal people, and a manufacturing method of the blood micro-molecular metabolin specific chromatogram. A micro-molecular metabolin comprises two blood metabolin marks, namely palmityl carnitine and carnitine; the molecular weights of the palmityl carnitine and the carnitine are 400.2634 and 161.20; and corresponding ions detected on a mass spectrum are 404.5532 and 160.7866. A clinical experiment shows that the accuracy of applying a chromatogram formed by a specific value of the two metabolism micro-molecules to judge the thyroid cancer is 74% and the accuracy of judging non-cancer (the benign thyroid tumor and the normal people) is 72.3%. The blood micro-molecular metabolin specific chromatogram disclosed by the invention has the advantage of high sensitivity and can be prepared into a diagnosis kit for screening and auxiliary diagnosis of the thyroid cancer.

A diagnostic test for ovarian cysts is based on the detection of mutations characteristic of the most common neoplasms giving rise to these lesions. With this test, tumor-specific mutations were detected in the cyst fluids of 19 of 24 (79%) borderline tumors and 28 of 31 (90%) malignant ovarian cancers. In contrast, we detected no mutations in the cyst fluids from 10 non-neoplastic cysts and 12 benign tumors. When categorized by the need for exploratory surgery (i.e., presence of a borderline tumor or malignant cancer), the sensitivity of this test was 85% and the specificity was 100%. These tests could inform the diagnosis of ovarian cysts and improve the clinical management of the large number of women with these lesions.

The invention discloses di(quinazoline-4-group)diselenide (which is an antitumor drug) or a pharmaceutically acceptable salt thereof which is a compound shown in a structural formula described in the specification. According to the invention, di(quinazoline-4-group)diselenide is synthesized from 4-chlorinated quinazoline, sodium diselenate or lithium diselenate in the presence of absolute ethyl alcohol serving as a solvent. The compound and the pharmaceutically acceptable salt thereof disclosed by the invention can be used for treating and preventing various benign tumors or malignant tumors, in particular have excellent multiplication inhibitory effect and good anti-cancer activity to the non-small cell lung cancer and breast cancer cells.